Imatinib mesylate therapy for polycythemia vera: Final result of a phase II study initiated in 2001

Roberto H. Nussenzveig, Jorge Cortes, Matjaz Sever, Alfonso Quintás-Cardama, Pat Ault, Taghi Manshouri, Carlos Bueso-Ramos, Josef T. Prchal, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journalArticle

Abstract

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by excessive production of red blood cells. Patients with PV are at a risk of thrombosis, bleeding, and transformation to myelofibrosis or acute myeloid leukemia. Therapy for PV is based on the use of phlebotomy, aspirin, and in high-risk patients, cytoreductive agents such as hydroxyurea. Anecdotal evidence suggests that imatinib mesylate, a selective tyrosine kinase inhibitor of ABL1, ARG, PDGFR, and KIT kinases has activity in PV. We conducted an open-label phase II clinical trial of imatinib at the standard dose of 400 mg daily in 24 patients with PV. The median duration of imatinib therapy was 5.1 months (range 0.2-86.4). Overall, 4 (17%) patients responded: one had a complete and three partial hematological response. The median time to response was 17.5 months (range 6-28), and the median duration of response was 17 months (range 9-68). No significant changes in JAK2 V617F mutation burden were noted during imatinib therapy when compared with pretreatment values (P = 0.46). Therapy with imatinib was generally well tolerated. Our data indicate that imatinib has minimal clinical activity in PV.

Original languageEnglish (US)
Pages (from-to)58-63
Number of pages6
JournalInternational Journal of Hematology
Volume90
Issue number1
DOIs
StatePublished - Jul 1 2009
Externally publishedYes

Fingerprint

Polycythemia Vera
Therapeutics
Phase II Clinical Trials
Primary Myelofibrosis
Phlebotomy
Hydroxyurea
Proxy
Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Aspirin
Imatinib Mesylate
Thrombosis
Phosphotransferases
Erythrocytes
Hemorrhage
Mutation
Neoplasms

Keywords

  • Imatinib mesylate
  • JAK2 mutation
  • Polycythemia vera

ASJC Scopus subject areas

  • Hematology

Cite this

Imatinib mesylate therapy for polycythemia vera : Final result of a phase II study initiated in 2001. / Nussenzveig, Roberto H.; Cortes, Jorge; Sever, Matjaz; Quintás-Cardama, Alfonso; Ault, Pat; Manshouri, Taghi; Bueso-Ramos, Carlos; Prchal, Josef T.; Kantarjian, Hagop; Verstovsek, Srdan.

In: International Journal of Hematology, Vol. 90, No. 1, 01.07.2009, p. 58-63.

Research output: Contribution to journalArticle

Nussenzveig, RH, Cortes, J, Sever, M, Quintás-Cardama, A, Ault, P, Manshouri, T, Bueso-Ramos, C, Prchal, JT, Kantarjian, H & Verstovsek, S 2009, 'Imatinib mesylate therapy for polycythemia vera: Final result of a phase II study initiated in 2001', International Journal of Hematology, vol. 90, no. 1, pp. 58-63. https://doi.org/10.1007/s12185-009-0345-y
Nussenzveig, Roberto H. ; Cortes, Jorge ; Sever, Matjaz ; Quintás-Cardama, Alfonso ; Ault, Pat ; Manshouri, Taghi ; Bueso-Ramos, Carlos ; Prchal, Josef T. ; Kantarjian, Hagop ; Verstovsek, Srdan. / Imatinib mesylate therapy for polycythemia vera : Final result of a phase II study initiated in 2001. In: International Journal of Hematology. 2009 ; Vol. 90, No. 1. pp. 58-63.
@article{a96194604bbe4880ae2dd79e1cd8dc13,
title = "Imatinib mesylate therapy for polycythemia vera: Final result of a phase II study initiated in 2001",
abstract = "Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by excessive production of red blood cells. Patients with PV are at a risk of thrombosis, bleeding, and transformation to myelofibrosis or acute myeloid leukemia. Therapy for PV is based on the use of phlebotomy, aspirin, and in high-risk patients, cytoreductive agents such as hydroxyurea. Anecdotal evidence suggests that imatinib mesylate, a selective tyrosine kinase inhibitor of ABL1, ARG, PDGFR, and KIT kinases has activity in PV. We conducted an open-label phase II clinical trial of imatinib at the standard dose of 400 mg daily in 24 patients with PV. The median duration of imatinib therapy was 5.1 months (range 0.2-86.4). Overall, 4 (17{\%}) patients responded: one had a complete and three partial hematological response. The median time to response was 17.5 months (range 6-28), and the median duration of response was 17 months (range 9-68). No significant changes in JAK2 V617F mutation burden were noted during imatinib therapy when compared with pretreatment values (P = 0.46). Therapy with imatinib was generally well tolerated. Our data indicate that imatinib has minimal clinical activity in PV.",
keywords = "Imatinib mesylate, JAK2 mutation, Polycythemia vera",
author = "Nussenzveig, {Roberto H.} and Jorge Cortes and Matjaz Sever and Alfonso Quint{\'a}s-Cardama and Pat Ault and Taghi Manshouri and Carlos Bueso-Ramos and Prchal, {Josef T.} and Hagop Kantarjian and Srdan Verstovsek",
year = "2009",
month = "7",
day = "1",
doi = "10.1007/s12185-009-0345-y",
language = "English (US)",
volume = "90",
pages = "58--63",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Imatinib mesylate therapy for polycythemia vera

T2 - Final result of a phase II study initiated in 2001

AU - Nussenzveig, Roberto H.

AU - Cortes, Jorge

AU - Sever, Matjaz

AU - Quintás-Cardama, Alfonso

AU - Ault, Pat

AU - Manshouri, Taghi

AU - Bueso-Ramos, Carlos

AU - Prchal, Josef T.

AU - Kantarjian, Hagop

AU - Verstovsek, Srdan

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by excessive production of red blood cells. Patients with PV are at a risk of thrombosis, bleeding, and transformation to myelofibrosis or acute myeloid leukemia. Therapy for PV is based on the use of phlebotomy, aspirin, and in high-risk patients, cytoreductive agents such as hydroxyurea. Anecdotal evidence suggests that imatinib mesylate, a selective tyrosine kinase inhibitor of ABL1, ARG, PDGFR, and KIT kinases has activity in PV. We conducted an open-label phase II clinical trial of imatinib at the standard dose of 400 mg daily in 24 patients with PV. The median duration of imatinib therapy was 5.1 months (range 0.2-86.4). Overall, 4 (17%) patients responded: one had a complete and three partial hematological response. The median time to response was 17.5 months (range 6-28), and the median duration of response was 17 months (range 9-68). No significant changes in JAK2 V617F mutation burden were noted during imatinib therapy when compared with pretreatment values (P = 0.46). Therapy with imatinib was generally well tolerated. Our data indicate that imatinib has minimal clinical activity in PV.

AB - Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by excessive production of red blood cells. Patients with PV are at a risk of thrombosis, bleeding, and transformation to myelofibrosis or acute myeloid leukemia. Therapy for PV is based on the use of phlebotomy, aspirin, and in high-risk patients, cytoreductive agents such as hydroxyurea. Anecdotal evidence suggests that imatinib mesylate, a selective tyrosine kinase inhibitor of ABL1, ARG, PDGFR, and KIT kinases has activity in PV. We conducted an open-label phase II clinical trial of imatinib at the standard dose of 400 mg daily in 24 patients with PV. The median duration of imatinib therapy was 5.1 months (range 0.2-86.4). Overall, 4 (17%) patients responded: one had a complete and three partial hematological response. The median time to response was 17.5 months (range 6-28), and the median duration of response was 17 months (range 9-68). No significant changes in JAK2 V617F mutation burden were noted during imatinib therapy when compared with pretreatment values (P = 0.46). Therapy with imatinib was generally well tolerated. Our data indicate that imatinib has minimal clinical activity in PV.

KW - Imatinib mesylate

KW - JAK2 mutation

KW - Polycythemia vera

UR - http://www.scopus.com/inward/record.url?scp=70350575320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350575320&partnerID=8YFLogxK

U2 - 10.1007/s12185-009-0345-y

DO - 10.1007/s12185-009-0345-y

M3 - Article

C2 - 19484334

AN - SCOPUS:70350575320

VL - 90

SP - 58

EP - 63

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 1

ER -